Precigen, Inc. reports developments as a commercial-stage biopharmaceutical company advancing precision medicines for difficult-to-treat diseases. Its news centers on PAPZIMEOS (zopapogene imadenovec-drba), an FDA-approved therapy for adults with recurrent respiratory papillomatosis, including commercialization, access, reimbursement, medical-publication updates, and adoption by treating physicians.
Company updates also cover financial results, business presentations, and pipeline activity across immuno-oncology, autoimmune disorders, and infectious diseases. Precigen’s recurring technology references include the AdenoVerse immunotherapy platform, UltraCAR-T programs, and related manufacturing capabilities used to support its precision-medicine portfolio.
On March 23, 2021, Precigen announced that the first patient has been dosed in a Phase I study of PRGN-2012, an off-the-shelf immunotherapy targeting recurrent respiratory papillomatosis (RRP). Recently granted Orphan Drug Designation by the FDA, PRGN-2012 utilizes gorilla adenovector technology to generate immune responses against HPV 6 and HPV 11. The trial aims to assess the safety and tolerability of PRGN-2012, involving up to 12 patients at maximum tolerated doses. This milestone could provide RRP patients with new therapeutic options, reducing the need for repeat surgeries.
Precigen, a biopharmaceutical company, announced that the FDA granted orphan drug designation for its investigational immunotherapy PRGN-2012, aimed at treating recurrent respiratory papillomatosis (RRP). This designation provides access to various incentives that may expedite development and commercialization. PRGN-2012, developed in collaboration with the National Cancer Institute, utilizes gorilla adenovector technology to prompt immune responses against HPV 6 and 11. The condition affects a small population, making novel treatments critically needed. CEO Helen Sabzevari emphasized the urgency for new therapies.
Precigen, Inc. (Nasdaq: PGEN) announced its financial results for Q4 and the full year 2020, reporting total revenues of $103.2 million, up from $90.7 million in 2019. The company experienced a net loss of $103.8 million or $(0.62) per share. Despite challenges, Precigen raised $129.4 million from a public offering in January 2021, ensuring cash support through 2023. Key developments include promising preliminary clinical data for PRGN-3005 and PRGN-3006 UltraCAR-T therapies, paving the way for future trials.
Precigen, Inc. (Nasdaq: PGEN) will release its fourth quarter and full year 2020 financial results after market close on March 1, 2021. A conference call is scheduled for 4:30 PM ET that day to discuss the results and provide a business update. Helen Sabzevari, PhD, President and CEO, will also present at the H.C. Wainwright Virtual Global Life Sciences Conference starting March 9, 2021. The company is focused on advancing gene and cell therapies targeting serious diseases, with ongoing clinical trials and a commitment to innovation in therapeutics.
Precigen, Inc. (Nasdaq: PGEN) announced that Dr. Helen Sabzevari, President and CEO, will participate in a virtual fireside chat at the Guggenheim Healthcare Talks Oncology Day on February 12, 2021, at 11:30 AM ET. Investors can access the live webcast through Precigen's website in the Events & Presentations section. Precigen focuses on innovative gene and cell therapies targeting serious diseases, with an emphasis on immuno-oncology, autoimmune disorders, and infectious diseases. For more information, visit www.precigen.com.
Precigen (Nasdaq: PGEN) announced the successful closing of its public offering of common stock, selling 17,250,000 shares at $7.50 each, including an exercised option for 2,250,000 shares. The offering generated approximately $129.4 million in gross proceeds before expenses. Wells Fargo Securities and Stifel served as joint book-running managers, and the offering was made under an effective shelf registration statement. Precigen aims to advance gene and cell therapies in immuno-oncology and other areas.
Precigen, Inc. (PGEN) announced a public offering of 15 million shares at $7.50 per share, generating approximately $112.5 million in gross proceeds. The underwriters have a 30-day option to purchase an additional 2.25 million shares. The offering, expected to close on January 26, 2021, will fund clinical and preclinical product development, working capital, and other corporate purposes. Wells Fargo Securities and Stifel are joint book-running managers.
Precigen, a biopharmaceutical company (Nasdaq: PGEN), has initiated an underwritten public offering of its common stock, granting underwriters a 30-day option for additional shares. The offering, subject to market conditions, will be conducted under an effective shelf registration statement. The offering details, including size and terms, will be disclosed in a preliminary prospectus supplement to be filed with the SEC. Wells Fargo Securities and Stifel are the joint book-running managers for this offering.
On January 13, 2021, Precigen (Nasdaq: PGEN) presented its clinical achievements and goals at the 39th Annual J.P. Morgan Healthcare Conference. Highlights included updates on PRGN-3005 and PRGN-3006 UltraCAR-T, alongside the new UltraCAR-T library approach aimed at personalized cancer therapies. Preliminary data from the Phase I/II study of PRGN-2009 for treating HPV-associated cancers was shared, indicating a strong immune response in patients. The company also announced advancements in other AdenoVerse immunotherapies targeting RRP and HBV, emphasizing its commitment to innovative therapies amidst COVID-19 challenges.
Precigen, Inc. (Nasdaq: PGEN) announced that Dr. Helen Sabzevari, President and CEO, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 3:40 PM ET. She will also take part in a panel discussion on precision medicine at the H.C. Wainwright BioConnect 2021 Conference on the same day at 12:00 PM ET. Live webcasts are available on Precigen’s website. The company focuses on advancing gene and cell therapies, addressing major health challenges.